



## MEDICAL POLICY No. 91545-R21

### BREAST RELATED PROCEDURES

Effective Date: December 1, 2025

Review Dates: 8/07, 8/08, 8/09, 4/10, 6/10,  
8/10, 8/11, 8/12, 6/13, 8/14, 8/15, 2/16, 2/17,  
2/18, 2/19, 2/20, 2/21, 8/21, 11/21, 8/22,  
2/23, 5/23, 5/24, 8/24, 8/25, 11/25

Date of Origin: August 8, 2007

Status: Current

*This policy includes the following previously separate policies: Breast Implants Explantation, Breast MRI, Breast Reconstruction and Revision Following Surgery for Breast Cancer, Male Gynecomastia, and Mastectomy for Intractable Breast Pain and Reduction Mammoplasty. Policy 91478 Breast Ductal Lavage has been retired. For prophylactic mastectomy, please see medical policy Prophylactic Cancer Risk Reduction Surgery 91508.*

Related medical policies:

- Cosmetic and Reconstructive Surgery Procedures # 91535
- Prophylactic Cancer Surgery # 91508
- Surgical Treatment of Lymphedema & Lipedema # 91631

#### Summary of Changes

Addition:

- **Scalp cooling devices for prevention of chemotherapy-induced Alopecia:**  
See Priority Health Medical Policy # 91535 *Cosmetic and Reconstructive Surgery Procedures*

Clarification:

- Photographic documentation must be submitted with all prior authorization requests.

## I. POLICY/CRITERIA

Note: Photographic documentation must be submitted with all prior authorization requests.

### A. Breast Implant Removal

1. Removal of breast implants that were placed for reconstruction after mastectomy, injury, congenital asymmetry, or augmentation mammoplasty is medically necessary according to InterQual criteria.
2. Removal of breast implants for the following conditions has been determined to not be medically necessary:
  - a. Breast malposition/asymmetry
  - b. Baker Class I or II Contracture
  - c. Anxiety related to the possibility of developing systemic disease, or anxiety related to the influence of breast implants on a current

autoimmune disease. It has not been proven that individuals with breast implants are at an increased risk of developing a systemic disease, or that the implants influence the current status of the systemic disease.

3. The requesting physician should supply clinical information related to the degree of contracture (e.g., Baker classification) or describe the etiology of the pain.
4. Replacement/reinsertion of a breast implant is a covered benefit only if the original placement surgery would have been a covered benefit (e.g., if original prosthesis was placed due to cancer surgery, replacement of the prosthesis is a covered benefit; if original surgical indication was cosmetic augmentation, replacement of the prosthesis is not a covered benefit).
5. En bloc capsulectomy:
  - a. Medically necessary for an established or suspected breast implant associated cancer.
  - b. All other indications are considered not medically necessary.

#### **B. Reduction Mammoplasty**

1. Unilateral and bilateral reduction mammoplasty may be considered medically necessary when applicable InterQual® criteria are met.
2. The following are not considered medically necessary:
  - a. Mastopexy procedures (e.g., breast ptosis). These procedures are cosmetic in nature and not performed to relieve pain due to macromastia.
  - b. Reduction mammoplasty for cosmetic purposes (to improve appearance).
  - c. Reduction mammoplasty to treat fibrocystic disease of the breasts.
  - d. Chronic intertrigo, eczema, dermatitis, and/or ulceration in the inframammary fold, in and of itself.
3. Coverage is limited to one reduction mammoplasty per member lifetime with Priority Health.

#### **C. Breast Reconstruction and Revision**

1. Breast reconstruction procedures are medically necessary according to InterQual criteria.
2. Procedures intended to change or restore appearance for cosmetic purposes are not medically necessary; See *Cosmetic and Reconstructive Surgery Procedures # 91535*.
3. Breast reconstruction surgery is medically necessary when incidental to disease and/or injury if:
  - a. A functional impairment is established, and surgery is intended to correct the functional impairment OR

- b. Breast reconstructive surgery is performed to correct asymmetry of a breast when surgery has been performed on the other breast incidental to disease or injury.
- 4. Autologous fat harvesting and grafting is considered reconstructive for the diseased/affected breast and non-diseased/unaffected/contralateral breast to produce a symmetrical appearance.
  - a. Due to necrosis or resorption of injected fat cells, transplant is limited to 150 cc per breast per procedure.
  - b. Fat harvesting (e.g., liposuction) used for body contouring, weight reduction, or for the transfer to another body region for alteration of physical appearance is considered cosmetic.
- 5. Neurotization or nerve coaptation performed in conjunction with a breast reconstruction procedure using autologous tissue (e.g. TUG flap) are considered experimental and investigational due to insufficient evidence of long-term impact on the of restoration of sensation to the reconstructed breast.

#### **D. Reconstruction and Revision for Breast Cancer**

This section applies to reconstruction and revision for breast cancer. It would also apply to women at high risk of breast cancer who require prophylactic mastectomy.

The Women's Health and Cancer Rights Act of 1998 (WHCRA) mandates coverage for all stages of breast reconstruction. Initial reconstruction can occur immediately after a mastectomy or be delayed until a member undergoes radiation or chemotherapy or determines whether she wants breast reconstruction. Some women will opt for immediate breast reconstruction after mastectomy, while some may prefer delayed reconstruction. While some reconstructions can be completed in a single procedure, other techniques may require two or more surgical procedures for completion of the reconstructive process. Breast reconstruction surgery is considered complete when reasonable symmetry is achieved, and when appropriate and desired nipple tattooing and reconstruction.

Further clarification of coverage for breast reconstruction and revision is outlined below.

- 1. Coverage for the breast affected by cancer, as well as for the breast(s) removed prophylactically (including bilateral prophylactic mastectomies). The following are covered benefits:
  - a. Treatment for complications of breast reconstruction including cellulitis, other infections, and lymphedema.
  - b. Revisions required by surgical complications including infection, hematoma or seroma, or skin or flap necrosis.

- c. Capsulotomies/capsulectomies for pain or contractures: See Breast Implant Removal section for medical necessity criteria.
  - d. Prosthesis removal for pain, contractures, rupture, leakage or infection: See Breast Implant Removal section for medical necessity criteria.
  - e. Scar revisions are only covered if one of the following apply:
    - i. The scar resulted from a serious complication such as infection or wound dehiscence from surgery or post-op period
    - ii. The scar revision is an integral (not incidental) part of another covered procedure.
2. Prophylactic mastectomy for breast cancer risk reduction
- a. See policy # 91508 *Prophylactic Cancer Surgery*
3. WHCRA does not mandate coverage for revision of a previously completed breast reconstruction to improve appearance.
- a. Reconstruction is not considered “incomplete” if the patient becomes dissatisfied with cosmetic results of reconstruction or where future medical or surgical conditions may alter results. Examples of non-covered conditions include nipple fading, loss of symmetry, for any reason including tissue atrophy after initial symmetry was achieved.
  - b. Revisions for aesthetic/cosmetic reasons beyond the original reconstructive surgery are not covered unless there were surgical complications such as cellulitis, other infections, lymphedema, hematoma, or significant skin or flap necrosis.
  - c. The member’s expectations and the limitations of surgical reconstruction must be thoroughly disclosed by the surgeon and understood by the member prior to reconstruction and documented as such in the signed informed consent.
4. Treatment or services to prevent chemotherapy induced hair loss (e.g., cooling therapy or devices during chemotherapy) are considered cosmetic and not covered.

**E. Microsurgical Lymph Node Transplantation for Post Mastectomy Lymphedema** is considered experimental and investigational.

Review for exceptions may be made in the following circumstances:

- 1. Chronic recurrent infection, or
- 2. Clinical functional impairment as defined as a condition which interferes with activities of daily living, and there is reasonable evidence to support that this intervention will correct the condition to which it is being attributed to. Further definition can be located in the Certificate of Coverage.

**F. Gynecomastia**

1. Unilateral and bilateral Gynecomastia in Adults and Adolescents: Simple mastectomy or reduction mammoplasty for gynecomastia may be considered medically necessary when applicable InterQual® are met: Reduction Mammoplasty, Male or Reduction Mammoplasty, Male (Adolescent).
2. Unilateral Gynecomastia in Adults: Excisional biopsies for adults with unilateral gynecomastia are medically necessary when malignancy is suspected.
3. Medicaid members: Prior authorization is required. All of the following documentation should be provided by the requesting physician:
  - a. Patient's age
  - b. Physical description of the enlarged breast including symmetry, mass, induration, and size
  - c. Medical history assessing the differential diagnosis including chronic diseases and medications.
  - d. Previous work-up including mammogram and fine needle aspirate, where appropriate for evaluation of unilateral gynecomastia or masses.  
High-quality original photographs for evaluation of the gynecomastia grade.

**G. Mastectomy for Intractable Breast Pain**

The efficacy and clinical application of mastectomy (simple or total) for intractable breast pain has not been proven to be a medically appropriate treatment and is not a covered benefit.

**H. Screening Mammography, Digital Breast Tomosynthesis, Ultrasound, Electrical Impedance Scanning, Breast MRI, and Breast-specific Gamma Imaging (BSGI)**

1. Screening Mammography
  - a. Conventional or digital mammography are medically necessary for breast cancer screening.
2. Coverage for screening mammography for an average risk woman is provided according to Michigan law:
  - a. Younger than 40 years of age: One mammogram in a five-year period.
  - b. 40 years of age and older: One mammogram per year.
3. Digital Breast Tomosynthesis (DBT)
  - a. A screening DBT is considered medically necessary for individuals that have dense breasts.

- b. A diagnostic DBT is considered medically necessary for individuals that have abnormal mammogram findings that require further imaging.
- 4. Breast MRI
  - a. A screening MRI is medically necessary when Evicore criteria are met.
- 5. Ultrasound, thermography, and electrical impedance scans for routine breast cancer screening are considered experimental and investigation because their clinical utility have not been demonstrated.
- 6. Breast Specific Gamma Imaging (BSGI) is considered experimental and investigational as an adjunct to mammography for imaging of breast tissue, for the detection of axillary metastases, staging the axillary lymph nodes in members with breast cancer, and to assess response to adjuvant chemotherapy in members with breast cancer and for all other indications because its effectiveness has not been established.
  - a. BSGI may be covered when part of an Institutional Review Board (IRB) approved clinical trial designed to assess its clinical utility for individuals with initial abnormal screening mammograms compared with other commonly used secondary screening techniques. Individual medical director review required.

**I. Bioimpedance (bioelectrical impedance spectroscopy)**

- 1. The use of bioimpedance also known as bioelectrical impedance spectroscopy (e.g. SOZO), in the detection, diagnosis, or surveillance of secondary, subclinical (Stage 0 or 1) breast cancer related lymphedema is medically necessary.
- 2. For indications other than cancer related lymphedema, the use of bioimpedance spectroscopy is not medically necessary as conventional measurement methods remain the standard of care. See *Medical Necessity* policy 91447.

**J. Scalp cooling devices for prevention of chemotherapy-induced alopecia:**

See Priority Health Medical Policy # 91535 *Cosmetic and Reconstructive Surgery Procedures*

**II. GOVERNMENT REGULATIONS**

Any federal or state mandates will take precedence over this medical coverage policy.

CMS Coverage Determinations	Title and Number

<b>National Coverage Determinations (NCDs)</b>	<a href="#">Breast Reconstruction Following Mastectomy (140.2)</a>
<b>Local Coverage Determinations</b>	
CGS Administrators, LLC	<a href="#">Cosmetic and Reconstructive Surgery (L39506)</a>
First Coast	<a href="#">Cosmetic and Reconstructive Surgery (L38914)</a>
Novitas	<a href="#">Cosmetic and Reconstructive Surgery (L35090)</a>
Palmetto GBA	<a href="#">Cosmetic and Reconstructive Surgery (L33428)</a>
Wisconsin Physicians Service Insurance Corporation	<a href="#">Cosmetic and Reconstructive Surgery (L39051)</a>

### III. GUIDELINES/POSITION STATEMENTS

Medical or Professional Society	Recommendation
Breast Surgery Collaborative Community (BSCC)	<a href="#">Consensus Statement from the Breast Surgery Collaborative Community (BSCC) on Capsulectomy Terminology and Management</a>
National Comprehensive Cancer Network (NCCN)	Breast Cancer Breast Cancer Risk Reduction Breast Cancer Screening and Diagnosis Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate
US Preventative Services Task Force (USPSTF)	<a href="#">Breast Cancer: Screening (2024)</a> <a href="#">BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing (2019)</a>

### IV. MEDICAL NECESSITY REVIEW

Prior authorization for certain drug, services, and procedures may or may not be required. In cases where prior authorization is required, providers will submit a request demonstrating that a drug, service, or procedure is medically necessary. For more information, please refer to the [Priority Health Provider Manual](#).

Breast Reduction Mammoplasty:

☒ Required: Self-Funded Plans and Medicaid: Prior authorization may apply based on diagnosis code. See Coding Sections below: Breast Mammoplasty, Breast Reconstruction and Revision, and Gynecomastia.

☒ Not Required: FF HMO, FF POS and Medicare. See plan documents for benefit details.

Submission of photographic documentation is required for all Prior Authorization requests.

To access Evicore guidelines: Log into [Priority Health Prism](#) → Authorizations → Authorization Criteria Lookup.

To access InterQual guidelines: Log into [Priority Health Prism](#) → Authorizations → Authorization Criteria Lookup.

## **V. APPLICATION TO PRODUCTS**

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

- ❖ **HMO/EPO:** *This policy applies to insured HMO/EPO plans.*
- ❖ **POS:** *This policy applies to insured POS plans.*
- ❖ **PPO:** *This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.*
- ❖ **ASO:** *For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.*
- ❖ **INDIVIDUAL:** *For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.*
- ❖ **MEDICARE:** *Coverage is determined by the Centers for Medicare and Medicaid Services (CMS) and/or the Evidence of Coverage (EOC); if a coverage determination has not been adopted by CMS, this policy applies.*
- ❖ **MEDICAID/HEALTHY MICHIGAN PLAN:** *For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule located at: [http://www.michigan.gov/mdch/0,1607,7-132-2945\\_42542\\_42543\\_42546\\_42551-159815--,00.html](http://www.michigan.gov/mdch/0,1607,7-132-2945_42542_42543_42546_42551-159815--,00.html). If there is a discrepancy between this policy and the Michigan Medicaid Provider Manual located at: [http://www.michigan.gov/mdch/0,1607,7-132-2945\\_5100-87572--,00.html](http://www.michigan.gov/mdch/0,1607,7-132-2945_5100-87572--,00.html), the Michigan Medicaid Provider Manual will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.*

## **VI. DESCRIPTION/BACKGROUND**

### **Breast Implant Removal**



A breast implant is a silicone shell filled with either silicone gel or saline. Some silicone gel may diffuse or “bleed” through the shell of an intact implant into the scar tissue or capsule that surrounds the implant. Rupture of an implant may be related to the length of time it has been in the body or it may also be related to force or trauma. All breast implants, like other medical devices, fail over time and need to be removed or replaced.

Significant local complications of breast implants may require removal of the implant. Contracture is the most common local complication of breast implants. Capsules of tightly-woven collagen fibers form as an immune response around a foreign body (e.g. breast implants, pacemakers, orthopedic joint prosthetics) tending to wall it off. Capsular contracture occurs when the capsule tightens and squeezes the implant. This contracture is a complication that can be very painful and distort the appearance of the implanted breast. Various systems have been used to classify breast contractures, but the most commonly used is the Baker classification. Four grades are described as follows:

Grade I	Augmented breast feels soft as a normal breast
Grade II	Augmented breast is less soft and implant can be palpated, but is not visible
Grade III	Augmented breast is firm, palpable and the implant (or distortion) is visible
Grade IV	Augmented breast is hard, painful, cold, tender and distorted

The exact cause of contracture is not known. However, some factors include bacterial contamination, silicone rupture or leakage, and hematoma.

When saline breast implants break, they often deflate quickly and can be easily removed. When silicone implants break they rarely deflate, and the silicone from the implant can leak. The differential diagnosis of silicone breast implant rupture includes intracapsular and extracapsular ruptures. If the extruded silicone is contained by this fibrous capsule the rupture is termed intracapsular. If the silicone gel is extruded beyond the capsule, the rupture is termed extracapsular. If intracapsular ruptures are early or focal, extensive gel bleeding has an appearance similar to that of extracapsular rupture by MRI. Extracapsular rupture involves free silicone in the breast parenchyma, which can simulate other breast masses, including breast cancer, at mammography and sonography. An intracapsular rupture can progress to outside of the capsule (extracapsular rupture), and when recognized, both conditions are generally agreed to indicate the need for removal of the implant. Clinically, extracapsular ruptures are often associated with a change in size and consistency of the breast. Extracapsular silicone has the potential to migrate, but most clinical complications have appeared to be limited to the breast and axillae in the form of granulomas (inflammatory nodules) and axillary lymphadenopathy. The development of scar tissue around a breast implant may necessitate a capsulotomy (surgical opening and release of scar tissue) or capsulectomy (surgical removal of the entire capsule containing the breast implant surrounded by abnormally thick, hardened tissue).

In 2024, a [consensus statement](#) on the terminology and management of breast implant capsules issued by the Breast Surgery Collaborative Community (BSCC), a consortium of physician representatives of the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society notes that an en bloc capsulectomy, defined as removal of the breast implant capsule with a margin of uninvolved tissue, is only necessary for patients with an established or suspected breast implant-associated cancer after appropriate medical workup. Additionally, BSCC issued consensus terminology for capsulectomy that included 1) total intact capsulectomy as the complete removal of the breast implant capsule as a single unit, 2) total capsulectomy/total precise Capsulectomy is the complete removal of the breast implant capsule, not necessarily done as a single unit or in one piece, and 3) partial capsulectomy is the removal of the breast implant capsule where some capsule is left behind.

### **Breast Reconstruction and Revision**

Breast reconstruction surgery includes those surgical procedures which are intended to restore the normal appearance of the breast. This restoration occurs after surgery, accidental injury, or trauma.

Mastectomy for cancer is the most common reason women seek breast reconstruction, but other conditions such as severe post radiation changes or congenital deformities are other reasons that a woman may seek breast reconstruction.

Techniques of reconstruction include tissue expansion, flap reconstruction, nipple areola reconstruction with subsequent implantation of a breast prosthesis. The tissue expander is a balloon-like device which is surgically placed under the chest tissue to create a breast-shaped space for the breast implant. On July 24, 2019, the FDA requested that Allergan, the manufacturer of a specific type of textured implant, [recall](#) specific models of its textured breast implants and textured tissue expanders from the U.S. market due to the risk of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Flap reconstruction allows for reconstruction using the patient's own tissues. Donor flap sites include the back, lower abdomen, buttocks, or lateral hip region. For a latissimus flap the latissimus dorsi muscle is used. This muscle is frequently used for reconstruction surgery due to its large size and versatility. For a TRAM flap (transverse rectus abdominus musculocutaneous flap) excess abdominal tissue is tunneled under the skin from the lower abdomen to the chest and used to replace the breast tissue. For a free flap, tissue from other body sites (such as buttock or lateral thigh region) is transferred to the chest. Examples of breast reconstruction techniques that use autologous tissue include, but may not be limited to:

- Deep circumflex iliac artery (DCIA)/Ruben's free flap
- Deep inferior epigastric perforator (DIEP)
- Gluteal artery perforator (GAP)
- Latissimus dorsi (LD)
- Profunda artery perforator (PAP)
- Superficial inferior epigastric artery (SIEA)

- Thoracodorsal artery perforator (TAP or TDAP)
- Transverse gracilis (TUG)
- Transverse rectus abdominus muscle (TRAM)

There are both Federal and Michigan state laws requiring health plans to cover breast reconstruction in certain defined circumstances. The federal and state requirements differ.

### **Autologous Fat Grafting**

High volume fat grafting, otherwise known as autologous fat grafting (AFG), for breast reconstruction is considered investigational. The volume of fat transfer that is generally agreed upon as “high-volume” is >100 cc per breast (Vizcay et al., 2020). Challenges with this procedure include fat necrosis, fat reabsorption, volume retention, and often the need for multiple procedures to achieve the desired outcome. The success of high volume transfer is limited by the size of the skin envelope, which affects the amount of fat that can be injected during one procedure (Mestak et al., 2013). Several external expansion devices, including the *Brava*® breast enhancement and shaping system, have been proposed as an adjunct to fat transfer procedures to increase the size of the skin envelope, however none of these devices are currently FDA approved for use within the United States. In a recent systematic review by Seth and colleagues (2024), a total of 35 studies comprising 3757 women undergoing autologous fat grafting to the breast were included. The average fat volume injected was 300 mL (range, 134 to 610 mL), and the average volume retention was 58% (range, 44% to 83%). The overall complication rate was 27.8%, with fat necrosis making up 43.7% of all complications. Volume retention was greater with supplementation of fat with platelet-rich plasma and stromal vascular fraction. The most common radiologic changes were fat necrosis (9.4%) and calcification (1.2%). After 1 year of follow-up, patient satisfaction was, on average, 92% (range, 83.2% to 97.5%). The included studies were of good quality and consisted of a moderate risk of bias.

### Medical Society Guidelines

American Society of Plastic Surgeons: *Post-Mastectomy Fat Graft/Fat Transfer ASPS Guiding Principles (2015)* “The quality of evidence to date indicates fat grafting to the post-mastectomy breast with no native breast tissue is a safe and effective modality in breast reconstruction...although there is no standardization for technique, detailed descriptions of fat graft harvest, preparation, storage, and injection have been described in the literature. Overall, autologous fat grafting to the postmastectomy breast with no remaining native tissue yields aesthetic improvement and significant patient satisfaction.”

### **Male Gynecomastia**

Gynecomastia is defined as the presence of an abnormal proliferation of breast tissue in males. It is a common breast lesion accounting for more than 65 percent of male breast disorders. Gynecomastia has a broad range of causes that are classified as either physiological or pathological, although in many cases no specific cause can be found

(idiopathic). In true gynecomastia, the breast enlargement is due to glandular breast tissue; in pseudo gynecomastia, the breast enlargement is secondary to fat accumulation; and both glandular and fat tissue are present in mixed gynecomastia.

Physiologic gynecomastia occurs most frequently during times of male hormonal changes, resulting from the effect of an altered estrogen/androgen balance on breast tissue or from the increased sensitivity of breast tissue to a normal estrogen level.

Pubertal gynecomastia is a common condition with an overall incidence of 38 percent in males 10 to 16 years of age, increasing to 65 percent at age 14, and dropping to 14 percent in 16-year-old boys. During adolescence, 75 percent of the gynecomastia cases are bilateral but the breasts are often affected to different degrees. Pubertal gynecomastia often regresses spontaneously in six months, 75 percent within two years of onset, and 90 percent resolve within three years of onset.

In adults, gynecomastia is associated with increasing age due to progressive testicular hypofunction, an increase in body fat, and an increase in the estrogen/androgen ratio.

Pathological gynecomastia is associated with both androgen deficiency and estrogen excess. Both causes may be due to medications, diseases related to endocrinologic abnormalities, tumors, chronic disease, chromosomal abnormalities, familial disorders, and other miscellaneous conditions. While there is always a concern when a mass is present, breast cancer accounts for only 0.2 percent of all malignancies in male patients. A suspicious mass or lesion requires biopsy.

Gynecomastia Scale adapted from the McKinney and Simon, Hoffman and Kohn scales:

- |                  |   |
|------------------|---|
| <b>Grade I</b>   | Small breast enlargement with localized button of tissue that is concentrated around the areola.                                  |
| <b>Grade II</b>  | Moderate breast enlargement exceeding areola boundaries with edges that are indistinct from the chest.                            |
| <b>Grade III</b> | Moderate breast enlargement exceeding areola boundaries with edges that are distinct from the chest with skin redundancy present. |
| <b>Grade IV</b>  | Marked breast enlargement with skin redundancy and feminization of the breast.  |

***Causes of Gynecomastia***

Physiologic	Tumor
Neonatal	Pituitary
Pubertal	Adrenal
Age	Testicular
Pathologic	Breast
Drugs, including marijuana	Chronic Disease
Endocrinopathy	Liver disease, cirrhosis
Primary hypogonadism	Renal failure
Secondary hypogonadism	Malnutrition
Hyperthyroidism	Pulmonary
Adrenal disorders	Nervous system damage
Familial	
Idiopathic	

### **Reduction Mammoplasty**

Macromastia is the development of abnormally large breasts. Macromastia that may require treatment is distinguished from large, normal breasts by the presence of persistent, painful symptoms and physical signs. These commonly include chronic mechanical upper back and/or neck and/or shoulder pain as the excessive breast weight adversely affects the supporting structures of the shoulders, neck, and trunk. Surgery solely performed to reshape the breasts, in order to improve appearance and self-esteem is considered to be cosmetic surgery.

Excessive breast weight may be reduced through a weight reduction management program or through surgical means. Reduction mammoplasty is the surgical excision of a substantial portion of the breast including the skin and the underlying glandular tissue, until a clinically normal size is obtained.

Inframammary intertrigo can occur where excessive breast tissue opposes the skin. Initiating factors include moisture and friction associated with an absence of air circulation in deep skin folds. In addition, candidal or bacterial infection may initiate or aggravate intertrigo (UpToDate, 2024). Reduction mammoplasty has not been established as an effective treatment for this condition. In a systematic review conducted by Mistiaen et al. (2010), 13 databases were sensitively searched for all types of empirical research relating to the prevention or treatment of intertrigo. Sixty-eight studies were identified that fulfilled the inclusion criteria. Only 4 studies were RCTs and these had a considerable risk of bias. Study populations were generally small. No studies were found about the prevention of intertrigo. The therapies concerned mostly the topical application of antimycotics, corticosteroids, antibiotics, antiseptics or a combination of these. Besides these pharmaceutical interventions,

surgical breast reduction was also studied. Although most study-authors were positive, the authors could not draw firm conclusions about any of the pharmaceutical interventions. Even patients that received placebo intervention showed improvement. There is weak evidence that reduction mammoplasty may be helpful to treat inframammary intertrigo. All research found had considerable risk of bias, prohibiting firm conclusions.

A breast lift, also known as mastopexy, raises the breasts by removing excess skin and tightening the surrounding tissue to create a more youthful breast contour. This procedure is considered cosmetic in nature. (American Society of Plastic Surgeons, 2024)

### **Mastectomy for Intractable Breast Pain**

Breast pain (mastalgia) is common in women and occasionally occurs in men. Although it is usually mild and self-limited, approximately 15 percent of affected women require treatment. Evaluation of breast pain is important to determine whether the pain is due to normal physiological changes related to hormonal fluctuation or to a pathologic process such as breast cancer. Unfortunately, studies specific to breast pain are limited and often small in number, not well designed, and with limited follow-up. (UpToDate, 2024)

Guidelines do not currently recommend mastectomy as an evidence-based treatment option for intractable breast pain.

### **Screening Mammography, Breast MRI, Digital Breast Tomosynthesis, Ultrasound, Thermography, Electrical Impedance Scanning, and Breast-specific gamma imaging (BSGI)**

#### *Screening Mammography*

Screening mammography involves radiographic (X-ray) examination of the breast performed at regular intervals, usually every 1 to 2 years, to detect breast cancer before it displays signs or symptoms. The goals of screening mammography for average risk women without any symptoms are to reduce breast cancer morbidity and mortality (illness and death). This can be accomplished by the accurate detection of the disease before it has metastasized (spread from the breast to another part of the body), when treatment can be less aggressive, and when the likelihood of long-term remission (decrease in symptoms) or cure is the highest.

According to the State of Michigan Insurance Code, breast cancer screening is defined as mammography using a standard 2-view per breast, low-dose radiographic examination of the breasts, and using equipment designed and dedicated specifically for mammography, in order to detect unsuspected breast cancer.

The Insurance Code goes on to define breast cancer diagnostic services as procedures intended to aid in the diagnosis of breast cancer, delivered on an inpatient or outpatient

basis, including but not limited to mammogram, mammography, surgical breast biopsy, and pathologic examination and interpretation.

### *Breast MRI*

Screening mammography detects less than half of the breast cancers in mutation carriers, perhaps owing to young age, dense breasts, or pathological features of the tumor. Cancers in mutation carriers grow rapidly; half of them appear in the interval between annual mammograms. Supplementing mammography with other imaging techniques, shorter screening intervals, or both may be valuable in mutation carriers. MRI may be a viable adjunct to mammography for breast cancer screening among carefully selected women at high risk for the disease due to familial or genetic predisposition. Although concerns regarding an increase in invasive follow-up procedures due to the reduced specificity of MRI screening may be warranted, the anxiety level regarding breast cancer among women with familial or genetic predisposition for the disease is already heightened; therefore, it is difficult to determine the clinical implication of additional follow-up procedures. The American Cancer Society does not recommend MRI as a screening test for average risk women.

### *Digital breast tomosynthesis (DBT)*

Breasts are made up of lobules, ducts, and fatty and fibrous connective tissue. Breast tissue may be called dense if there is a lot of fibrous or glandular tissue and not much fat in the breasts. (ACS, 2019). Breast density should be assessed on the standard digital mammogram or on the synthesized mammogram (ACR, 2013). Breast Imaging Reporting and Data System (BI-RADS) outlines four categories of mammographic density: almost entirely fatty, scattered areas of fibroglandular density, heterogeneously dense, and extremely dense. The exact relationship between breast density and breast cancer is still unknown. However, in breasts that are dense, cancer can be hard to see on a mammogram. DBT, also commonly called 3D mammography, provides images of the breast in “slices” from many different angles allowing for improvement in cancer detection, characterization, and localization. DBT reduces the masking effects of superimposed tissue, allowing better visualization of true lesions and decreasing summation shadow. Inclusion of DBT with standard two-dimensional digital mammography improves cancer detection while simultaneously reducing the rate of false positive examinations (ACR, 2013).

### *Ultrasound*

Breast ultrasound uses sound waves and their echoes to make computer pictures of the inside of the breast. It can show certain breast changes, like fluid-filled cysts, that can be harder to see on mammograms. Ultrasound is not typically used as a routine screening test for breast cancer. It can be useful for looking at some breast changes, such as lumps (especially those that can be felt but not seen on a mammogram). Ultrasound can be especially helpful in women with dense breast tissue, which can make it hard to see abnormal areas on mammograms. It also can be used to get a better

look at a suspicious area that was seen on a mammogram. Ultrasound is useful because it can often tell the difference between fluid-filled masses like cysts and solid masses (American Cancer Society, 2024)

According to the American College of Radiology Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations (2023), “Although not indicated for the majority of patients at significantly elevated risk, further comparative studies will be crucial to determine if ultrasound is an optimal choice for breast cancer screening for women who have dense breasts as their only risk factor.”

### *Thermography*

Thermography uses an infrared camera to detect heat emissions from the targeted body region. Digital infrared thermal imaging is the thermography used to diagnose breast cancer. The concept behind this test is that as cancer cells multiply, they need more oxygen-rich blood for growth. As there is an increase in blood flow to the tumor, the temperature around the tumor also increases. Malignant cells discharge nitric oxide into the bloodstream and cause impairment in the microcirculation. This released nitric oxide, along with the active growth of the cancerous cells, increases blood circulation and temperature in that region. Therefore, evaluating these differences in temperature leads to the detection of the malignant region in the breast. (Rakhunde et al, 2022)

According to National Comprehensive Cancer Network (NCCN) guidelines for Breast Cancer Screening and Diagnosis, “*Current evidence does not support the routine use of thermography as a screening procedure*” (NCCN, 2024)

### *Electrical Impedance Scanning*

Electrical impedance tomography (EIT) is a non-invasive, mobile screening method which does not use ionizing radiation. It is based on the theory that cancer cells display altered local dielectric properties, thus demonstrating measurably higher conductivity values. (Akhtari-Zavare M, et al, 2015) Electrical impedance scanning is not an established modality for breast cancer screening at this time. A large systematic review and meta-analysis conducted by Gatabi and colleagues (2022) using search terms "EIT" and "Breast Cancer" with the goal of establishing the accuracy of electrical impedance tomography for breast cancer screening found EIT had an overall pooled sensitivity and specificity of 75.88% (95% CI, 61.92% to 85.89%) and 82.04% (95% CI, 69.72% to 90.06%), respectively. The pooled diagnostic odds ratio was 14.37 (95% CI, 6.22% to 33.20%), and the pooled effect of accuracy was 0.79 with 95% CI (0.73, 0.83). The authors concluded that this study showed that EIT can be used as a useful method alongside mammography. EIT sensitivity could not be compared with the sensitivity of MRI, and more large-scale studies will be needed to support these findings.

Breast-specific gamma imaging (BSGI) was developed as a confirmatory test used after mammography and a clinical breast exam. This technique detects



abnormal breast tissue based on uptake of technetium-99m sestamibi, a radioactive agent that emits gamma rays and that tends to accumulate in cancerous breast tissue. BSGI is typically performed on an outpatient basis by a nuclear medicine technician with results interpreted by a radiologist or physician specializing in nuclear medicine.

Results of the available studies do not provide conclusive evidence that BSGI can be relied on rather than biopsy in women who have suspicious breast lesions. Studies that compared the sensitivity of BSGI with other techniques showed no statistically significant differences in the sensitivity of BSGI, mammography, ultrasonography, and MRI. Although further studies may indicate that BSGI has greater sensitivity than ultrasonography and MRI, BSGI has the disadvantage that it requires radiation exposure. In addition, unlike biopsy, BSGI does not provide a definitive diagnosis. Further studies are needed to determine the clinical role of BSGI versus MRI and ultrasonography as adjuncts to mammography and clinical breast exams as well as to validate the impact of BSGI on patient survival.

### **Microsurgical Lymph Node Transplantation for Post Mastectomy Lymphedema**

The vascular lymph node transplant (VLNT) procedure consists of a transfer of lymph node flaps with their vascular supply from a donor site (including the axillary, inguinal, or cervical lymph node basins, or from intra-abdominal donor sites) to the axilla, forearm, or wrist of the lymphedematous upper extremity. The exact physiological response to this procedure has yet to be confirmed. A recent systematic review by Doubblestein et al (2023) investigated which rehabilitation interventions contribute to the highest level of pre- and post-microsurgical outcomes. Thirteen studies met all inclusion criteria and revealed that there is a dearth of high-quality literature leading to a gap in knowledge as to how breast cancer-related lymphedema (BCRL) microsurgical and conservative interventions complement each other. Furthermore, peri-operative outcome measures were inconsistent. The authors concluded that peri-operative guidelines are needed to bridge the knowledge and care gap between lymphedema surgeons and therapists.

In a consensus conference held in 2017 by the American Association of Plastic Surgeons, an exhaustive review of existing literature was performed to conduct a systematic review and meta-analysis of controlled trials with the goal to examine both the benefits and risks of surgical treatment and surgical prevention of upper and lower extremity lymphedema. Panel members found that there is evidence to support that vascular lymph node transplantation can be effective in reducing severity of lymphedema (grade 1B). Currently, there is no consensus on which procedure (lymphovenous bypass versus vascular lymph node transplantation) is more effective (grade 2C). Ultimately, the authors concluded that many questions remain unanswered and more studies with longer follow-up are required to confirm this benefit (Chang et al, 2021).

### **Bioimpedance for Lymphedema**

Lymphedema (LE) is the accumulation of protein-rich fluids in tissue that has inadequate lymphatic drainage. The cause of this inadequate drainage can be congenital abnormalities of the lymphatic system (primary LE), or, as is more often the case, by acquired damage to the lymphatic system (secondary LE). A common cause of secondary LE is treatment of breast cancer with modalities such as axillary lymph node dissection (ALND), mastectomy, lumpectomy, and radiation therapy. Due to the chronic nature of lymphedema, a preventive approach has the potential to spare patients a great deal of morbidity.

Patients who have lymphedema may present with decreased function due to limbs that are swollen; feel full or heavy; have decreased flexibility; and have skin that feels tight, has changed texture, or developed lesions (National Cancer Institute – Lymphedema PDQ). Pitting edema (in which a dent in the skin is present after it is pressed) indicates swelling is primarily due to lymphatic fluid accumulation in soft tissues. Absence of pitting indicates more progressed lymphedema with swelling primarily due to increased fat deposition and fibrosis. Patients may also present with infections of the limb, such as cellulitis or lymphangitis, due to local immune deficiency caused by lymphatic impairment. Breast cancer treatment–related upper extremity lymphedema usually develops 8 months to 3 years after surgery; lower extremity lymphedema caused by pelvic or inguinal lymph node dissection tends to have a more rapid onset, often occurring 3 to 6 months after surgery.

Bioimpedance analysis (BIA) is a noninvasive method that detects increases in tissue fluid based on increased flow of electricity. This technique is rapid and relies on small electrical currents that do not cause any pain or discomfort. BIA relies on the differing abilities of body tissues to conduct low level (200 to 800 microamperes) alternating electrical currents. Although lymph, blood, and muscle tissue exhibit low impedance (or resistance) to the flow of electricity, fat and bone exhibit high impedance. Changes in bioimpedance can be used to measure changes in body fluid composition due to conditions such as diabetes, cirrhosis of the liver, and lymphedema (LE). BIA can be performed at a single frequency or multiple frequencies ranging from 5000 to 1 million cycles per second. Multiple frequency BIA (MFBIA) is often referred to as bioimpedance spectroscopy (BIS) to distinguish it from the single frequency BIA (SFBIA). NCCN’s Survivorship: Lymphedema (2023) recommends survivors at risk for lymphedema be regularly screened for lymphedema by symptom assessment, clinical exam, and, if available, bioimpedance spectroscopy. Early detection/diagnosis and early referral are key for optimal lymphedema management because stages 0 and 1 are reversible, whereas stages 2 and 3 are less responsive to treatment. The stages of lymphedema are defined as (NCI Lymphedema PDQ; International Society of Lymphology, 2016):

- Stage 0 (latent/subclinical): Lymphatic dysfunction without swelling; subtle symptoms, such as a feeling of heaviness or fatigue in the limb, may be present.
- Stage 1 (spontaneously reversible): Accumulation of fluid and protein causing swelling; pitting edema may be evident; increased girth, heaviness,

and/or stiffness of affected area. For the limbs, swelling is relieved with elevation.

- Stage 2 (irreversible): Spongy tissue consistency, with pitting edema that becomes less evident as swelling increases; tissue fibrosis causing hardness and increase in size. For the limbs, swelling is not relieved with elevation.
- Stage 3 (lymphostatic elephantiasis): Severe dry, scaly, thickened skin; increased swelling and girth of affected area; can be debilitating. In the limbs, fluid leakage and blisters are common. Fungal infection and papilloma may occur. Pitting can be absent due to progressive deposition of fat and fibrosis, which is the hallmark of later stage lymphedema.

### Nerve Procedures

Nerve repair procedures on the breast, specifically breast neurotization or resensation, aim to restore feeling to the breasts and/or areolas after procedures like mastectomy and breast reconstruction. This involves reconnecting nerves in the chest with those in the reconstructed tissue using methods like nerve grafting, nerve conduits, and direct nerve coaptation. The goal is to mitigate the loss of sensation that is common after breast reconstruction and restore the ability to feel temperature, pressure, etc to the area. The breast skin is predominantly innervated by the second until sixth intercostal nerves. Some nerves can occasionally be spared during mastectomy, especially during nipple-sparing mastectomy, but transection of sensory nerves is inevitable and leads to impaired sensation. Coaptation between the third anterior intercostal nerve and a sensory nerve from the donor site improves sensory recovery. The donor site and nerve vary, depending on the flap type chosen. The sensory nerves from the commonly used abdominal deep inferior epigastric perforator artery (DIEP) flap originate from the 7th until 12th thoracic spinal nerves. Non-abdominal flaps, including the back, buttocks, or thigh area, can also be accompanied with a sensory nerve. Nerve coaptation can be performed directly, or by using grafts or conduits to obtain tensionless repair if necessary. It can be utilized in both immediate as well as delayed autologous breast reconstruction. (Bubberman et al., 2023)

A small prospective comparative study by Beugels and colleagues (2019) evaluated patients who underwent either innervated or non-innervated deep inferior epigastric perforator artery flap (DIEP) procedures with the goal of evaluating the effect of nerve coaptation on the sensory recovery of the breast. Nerve coaptation was performed to the anterior cutaneous branch of the third intercostal nerve. Semmes-Weinstein monofilaments were used for sensory testing of the native skin and flap skin. A total of 48 innervated DIEP flaps in 36 patients and 61 non-innervated DIEP flaps in 45 patients were tested at different follow-up time points. Nerve coaptation was significantly associated with lower monofilament values in all areas of the reconstructed breast (adjusted difference, -1.2;  $p < 0.001$ ), which indicated that sensory recovery of the breast was significantly better in innervated compared with noninnervated DIEP flaps. For every month of follow-up, the mean monofilament value decreased by 0.083 in innervated flaps ( $p < 0.001$ ) and 0.012 in noninnervated flaps ( $p < 0.001$ ). Nerve coaptation significantly improved sensation in both immediate and delayed reconstructions. The authors concluded that nerve coaptation in DIEP flap breast

reconstruction is associated with a significantly better sensory recovery in all areas of the reconstructed breast compared with non-innervated flaps.

Weissler et al (2018) conducted a review of 37 articles accounting of 1299 patients to appraise and summarize the literature on breast sensation following implant-based and autologous reconstruction with and without neurotization, and to identify methodologic discrepancies to provide a more standardized template for future research. The authors conducted a present the lack of prospective randomized trials, discrepancies in sensory testing modalities and time to testing, and other notable study limitations confound the interpretation of published outcomes.

Unfortunately, there is very limited data on nerve repair procedures, and further studies are needed to demonstrate the reproducibility of nerve repair and sensory return in the breast.

## **VII. CODING INFORMATION**

### **A. Breast Implant Removal**

**ICD-10 Codes** that may apply:

N64.9	Disorder of breast, unspecified
T85.44xA - T85.44xS	Capsular contracture of breast implant
T85.828A - T85.828S	Fibrosis due to internal prosthetic devices, implants and grafts
T85.848A - T85.848S	Pain due to internal prosthetic devices, implants and grafts
T85.898A - T85.89S	Other specified complication of internal prosthetic devices, implants and grafts

**CPT/HCPCS Codes**

19328	Removal of intact breast implant
19330	Removal of ruptured breast implant, including implant contents (eg saline, silicone gel)

### **B. Reduction Mammoplasty**

**ICD-10 Codes** that may apply:

N62	Hypertrophy of breast
-----	-----------------------

**CPT/HCPCS Code**

19318	Reduction Mammoplasty
-------	-----------------------

### **C. Breast Reconstruction and Revision**

**ICD-10 Codes** that support medical necessity:

C50.011 - C50.929	Malignant neoplasm of breast
C79.81	Secondary malignant neoplasm of breast
D05.00 - D05.92	Lobular carcinoma in situ of breast
D07.30	Carcinoma in situ of unspecified female genital organs
Z40.01	Encounter for prophylactic removal of breast

Z42.1	Encounter for breast reconstruction following mastectomy
Z42.8	Encounter for other plastic and reconstructive surgery following medical procedure or healed injury
Z85.3	Personal history of malignant neoplasm of breast
Z90.10 – Z90.13	Acquired absence of breast and nipple
Z98.82	Breast implant status
N64.89	Other specified disorders of breast
T85.44xA - T85.44xS	Capsular contracture of breast implant,
T85.41xA - T85.49xS	Mechanical complication of breast prosthesis and implant
T85.79xA - T85.79xS	Infection and inflammatory reaction due to other internal prosthetic devices, implants and grafts
T85.828A-T85.828S	Fibrosis due to other internal prosthetic devices, implants and grafts
T85.848A-T85.848S	Pain due to other internal prosthetic devices, implants and grafts
T85.898A-T85.898S	Other specified complication of other internal prosthetic devices, implants and grafts

**CPT/HCPCS Codes**

*The above diagnoses support medical necessity for the following procedures. All other indications must be prior authorized.*

11920	Tattooing, intradermal introduction of insoluble opaque pigments to correct color defects of skin, including micropigmentation; 6.0 sq cm or less
11921	Tattooing, intradermal introduction of insoluble opaque pigments to correct color defects of skin, including micropigmentation; 6.1 to 20.0 sq cm
11922	Tattooing, intradermal introduction of insoluble opaque pigments to correct color defects of skin, including micropigmentation; each additional 20.0 sq cm (List separately in addition to code for primary procedure)
11970	Replacement of tissue expander with permanent implant
11971	Removal of tissue expander(s) without insertion of implant
19316	Mastopexy
19318	Breast Reduction
19325	Breast augmentation; with implant
19340	Insertion or replacement of breast implant on the same day of mastectomy (ie, immediate)
19342	Insertion or replacement of breast implant on separate day from mastectomy
19350	Nipple/areola reconstruction
19357	Tissue expander or placement in breast reconstruction, including subsequent expansion (s)
19361	Breast reconstruction with latissimus dorsi flap,
19364	Breast reconstruction with free flap (ex fTram, DIEP, SIEA, GAP flap)
19367	Breast reconstruction with with single pedicled transverse rectus abdominis myocutaneous (TRAM) flap
19368	Breast reconstruction with single pedicled transverse rectus abdominis myocutaneous (TRAM) flap requiring separate microvascular anastomosis (supercharging)
19369	Breast reconstruction with bipedicled transverse rectus abdominis myocutaneous (TRAM) flap

- 19370 Revision of peri-implant capsule, breast, including capsulotomy, capsulorrhaphy, and/or partial capsulectomy
- 19371 Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents
- 19380 Revision of reconstructed breast (eg, significant removal of tissue, re-advancement and/or re-inset of flaps in autologous reconstruction or significant capsular revision combined with soft tissue excision in implant-based reconstruction)
- 19396 Preparation of moulage for custom breast implant
  
- C1789 Prosthesis, breast (implantable)  
 Bill with Revenue Code 0272 Sterile supply  
*(not separately payable for Priority Health Medicaid)*
- L8039 Breast prosthesis, not otherwise specified  
 Billed with Revenue Code 0274 Prosthetic/orthotic devicesd  
*(not separately payable for Priority Health Medicaid)*
- L8600 Implantable breast prosthesis, silicone or equal  
 Billed with Revenue Code 0278 Other implants  
*(Not separately payable for Priority Health Medicaid)*
  
- S2066 Breast reconstruction with gluteal artery perforator (GAP) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateral *(S Code is not covered for Priority Health Medicaid and Priority Health Medicare)*
- S2067 Breast reconstruction of a single breast with "stacked" deep inferior epigastric perforator (DIEP) flap(s) and/or gluteal artery perforator (GAP) flap(s), including harvesting of the flap(s), microvascular transfer, closure of donor site(s) and shaping the flap into a breast, unilateral *(S Code is not covered for Priority Health Medicaid and Priority Health Medicare)*
- S2068 Breast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferior epigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateral *(S Code is not covered for Priority Health Medicaid and Priority Health Medicare)*

### **Not Covered**

- 0662T Scalp cooling, mechanical; initial measurement and calibration of cap *(Not Separately Payable)*
- 0663T Scalp cooling, mechanical; placement of device, monitoring, and removal of device (List separately in addition to code for primary procedure) *(Not Separately Payable)*
  
- 0694T 3-dimensional volumetric imaging and reconstruction of breast or axillary lymph node tissue, each excised specimen, 3-dimensional automatic specimen reorientation, interpretation and report, real-time intraoperative
- 0857T Opto-acoustic imaging, breast, unilateral, including axilla when performed, real-time with image documentation, augmentative analysis and report (List separately in addition to code for primary procedure)

0945T Intraoperative assessment for abnormal (tumor) tissue, in-vivo, following partial mastectomy (e.g., lumpectomy) using computer-aided fluorescence imaging (List separately in addition to code for primary procedure)

**D. Microsurgical Lymph Node Transplantation for Post mastectomy Lymphedema**

**ICD-10 Codes** that may apply:

I97.2 Post mastectomy lymphedema syndrome

**CPT/HCPCS Codes:**

38999 Unlisted procedure, hemic or lymphatic system (Explanatory notes must accompany claim)

**E. Gynecomastia**

**ICD-10 Codes** that support medical necessity:

N62 Hypertrophy of breast

**CPT/HCPCS Codes**

19300 Mastectomy for gynecomastia

19303 Mastectomy, simple, complete

19318 Reduction Mammoplasty

**Special Note:** Most benefit plans have a 50% co-pay on professional fees effective 1/1/2003. A rider allowing coverage at a higher level is available to employers.

**F. Mastectomy for Intractable Breast Pain (*Not covered*)**

**ICD-10 Codes** that apply:

N64.4 Mastodynia

**CPT/HCPCS Codes**

19301 Mastectomy, partial; (e.g., lumpectomy, tylectomy, quadrantectomy, segmentectomy)

19302 Mastectomy, partial; with axillary lymphadenectomy (e.g., lumpectomy, tylectomy, quadrantectomy, segmentectomy); with axillary lymphadenectomy

19303 Mastectomy, simple, complete

19305 Mastectomy, radical, including pectoral muscles, axillary lymph nodes

19306 Mastectomy, radical, including pectoral muscles, axillary and internal mammary lymph nodes (Urban type operation)

19307 Mastectomy, modified radical, including axillary lymph nodes, with or without pectoralis minor muscle, but excluding pectoralis major muscle

**G. Mammography, Digital Breast Tomosynthesis (DBT), Breast MRI and Breast Specific Gamma Imaging (BSGI)**

Diagnostic Procedures:

76641 Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; complete

- 76642    Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited
- 77046    Magnetic resonance imaging, breast, without contrast material; unilateral
- 77047    Magnetic resonance imaging, breast, without contrast material; bilateral
- 77048    Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral
- 77049    Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed, bilateral
- 77065    Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral
- 77066    Diagnostic mammography, including computer-aided detection (CAD) when performed; bilateral
- 77061    Digital breast tomosynthesis; unilateral
- 77062    Digital breast tomosynthesis; bilateral
  
- G0279    Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)

**Screening Procedures:**

- 77067    Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed
- 77063    Screening digital breast tomosynthesis, bilateral (List separately in addition to code for primary procedure)

**ICD-10 Codes that support preventive benefit for the following diagnostic procedures if performed for screening indication and converted to diagnostic**

- Z12.31    Encounter for screening mammogram for malignant neoplasm of breast
- Z12.39    Encounter for other screening for malignant neoplasm of breast
- Z80.3    Family history of malignant neoplasm of breast
- Z85.3    Personal history of malignant neoplasm of breast

**CPT/HCPCS Codes**

- 77065    Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral
- 77066    Diagnostic mammography, including computer-aided detection (CAD) when performed; bilateral
- 77061    Diagnostic digital breast tomosynthesis; unilateral
- 77062    Diagnostic digital breast tomosynthesis; bilateral
- G0279    Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)

**BSGI****ICD-10 Codes that are not covered:**

- C50.011 - C50.929    Malignant neoplasm of breast
- D05.00 – D05.92    Carcinoma in situ of breast
- R92.0 - R92.8    Abnormal and inconclusive findings on diagnostic imaging of breast



Z12.31	Encounter for screening mammogram for malignant neoplasm of breast
Z12.39	Encounter for other screening for malignant neoplasm of breast
Z40.01	Encounter for prophylactic removal of breast
Z80.3	Family history of malignant neoplasm of breast
Z85.3	Personal history of malignant neoplasm of breast

**CPT/HCPCS Codes:**

*Not covered for any indication*

S8080 Scintimammography (radioimmunosintigraphy of the breast), unilateral, including supply of radiopharmaceutical

*Not covered for the diagnoses listed above*

78800 Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); limited area

78801 Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); multiple areas

**H. Bioimpedance (bioelectrical impedance spectroscopy)**

**ICD-10 Codes that support medical necessity:**

C50-C50.929 Malignant neoplasm of breast

D05-D05.92 Carcinoma in situ of breast

**CPT/HCPCS Codes**

93702 Bioimpedance spectroscopy (BIS), extracellular fluid analysis for lymphedema assessment(s)

**I. Other Non Covered Codes:**

0970T Ablation, benign breast tumor (eg, fibroadenoma), percutaneous, laser, including imaging guidance when performed, each tumor

0971T Ablation, malignant breast tumor(s), percutaneous, laser, including imaging guidance when performed, unilateral

**VIII. REFERENCES***Bioimpedance*

1. International Society of Lymphology. Executive Committee. The Diagnosis and Treatment of Peripheral Lymphedema: 2016 Consensus Document of the International Society of Lymphology. *Lymphology* 2016;49:170-184.
2. Jung M, et al. Reference values of bioelectrical impedance analysis for detecting breast cancer-related lymphedema. *Medicine (Baltimore)*. 2018 Nov;97(44):e12945. doi: 10.1097/MD.00000000000012945.
3. Kilgore LJ, et al. Reducing Breast Cancer-Related Lymphedema (BCRL) Through Prospective Surveillance Monitoring Using Bioimpedance

- Spectroscopy (BIS) and Patient Directed Self-Interventions. *Ann Surg Oncol*. 2018 Oct;25(10):2948-2952. doi: 10.1245/s10434-018-6601-8. Epub 2018 Jul 9.
4. Koelmeyer La, et al. Early surveillance is associated with less incidence and severity of breast cancer-related lymphedema compared with a traditional referral model of care. *Cancer*. 2019 Mar 15;125(6):854-862.
  5. Levenhagen K, Davies C, Perdomo M, Ryans K, Gilchrist L. Diagnosis of Upper-Quadrant Lymphedema Secondary to Cancer: Clinical Practice Guideline From the Oncology Section of APTA. *Rehabil Oncol*. 2017 Jul;35(3):E1-E18. doi: 10.1097/01.REO.0000000000000073. Epub 2017 Jun 30. PMID: 28748128; PMCID: PMC5497787.
  6. National Cancer Institute. [Lymphedema \(PDQ\)–Health Professional Version](#). Last updated 12/18/2024. (Accessed April 2, 2025).
  7. National Lymphedema Network. [Screening and Early Detection](#). (Accessed April 2, 2025).
  8. Ridner SH, et al. A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement for the Prevention of Lymphedema Following Treatment for Breast Cancer: Interim Analysis. *Ann Surg Oncol*. 2019 May 3. doi: 10.1245/s10434-019-07344-5.
  9. Shah C, Whitworth P, Valente S, Schwarz GS, Kruse M, Kohli M, Brownson K, Lawson L, Dupree B, Vicini FA. Bioimpedance spectroscopy for breast cancer-related lymphedema assessment: clinical practice guidelines. *Breast Cancer Res Treat*. 2023 Feb;198(1):1-9. doi: 10.1007/s10549-022-06850-7. Epub 2022 Dec 24. PMID: 36566297; PMCID: PMC9883343.
  10. Steele ML, et al. Normative Interlimb Impedance Ratios: Implications for Early Diagnosis of Uni- and Bilateral, Upper and Lower Limb Lymphedema. *Lymphat Res Biol*. 2018 Oct 2. doi: 10.1089/lrb.2017.0082
  - Vicini F, et al. Correlation of Bioimpedance Spectroscopy with Risk Factors for the Development of Breast Cancer-Related Lymphedema. *Lymphat Res Biol*. 2018 Dec 1; 16(6): 533–537. doi: 10.1089/lrb.2017.0078.
  11. US Food & Drug Administration. [Impedance Plethysmograph. Section 510\(k\) premarket](#). (Accessed April 2, 2025).
  12. Whitworth PW, Shah C, Vicini F, Cooper A. Preventing Breast Cancer-Related Lymphedema in High-Risk Patients: The Impact of a Structured Surveillance Protocol Using Bioimpedance Spectroscopy. *Front Oncol*. 2018 Jun 12;8:197. doi: 10.3389/fonc.2018.00197. PMID: 29946531; PMCID: PMC6006520.

#### *Breast Implant Removal*

13. American Society of Plastic Surgeons, [Silicone breast Implant Surgery](#), (Accessed April 2, 2025).
14. Centers for Medicare and Medicaid, Complete Guide to Medicare Coverage Issues, Medicare National Coverage Determinations (NCD140.2, 140.4) [Pub. 100-03], Ingenix, Inc., May 2006.

15. Nagelin-Anderson, E., and D. Zuckerman, [Complications of Saline Breast implants: What You Should Know Before You Decide on Augmentation, Issue Brief, National Research Center for Women & Families](#). Available ( Accessed April 2, 2025).
16. Pittet, B., Montandon, D., and D. Pittet, Infection in breast implants, *Lancet Infectious Disease*, Vol. 5, 94-106, February 2005.
17. United States Food and Drug Administration (FDA), [Breast Implant Consumer Handbook](#) (Accessed April 2, 2025).
18. Wisconsin Physicians Service (WPS), [Local Coverage Decision \(L39051\) Cosmetic and Reconstructive Surgery](#)(Accessed April 2, 2025).

*Breast Reconstruction and Revision*

19. American Society of Plastic Surgeons. [Post-Mastectomy Fat Graft/Fat Transfer ASPS Guiding Principles \(2015\)](#) (Accessed April 2, 2025).
20. Centers for Medicare and Medicaid Services. [National Coverage Determination \(NCD\) for Breast Reconstruction Following Mastectomy \(140.2\)](#) (Accessed April 2, 2025)
21. Chang CS, Lanni MA, Mirzabeigi MN, Bucky LP. Large-Volume Fat Grafting: Identifying Risk Factors for Fat Necrosis. *Plast Reconstr Surg*. 2022 Nov 1;150(5):941e-949e.
22. Mestak O, et al. Breast Reconstruction after a Bilateral Mastectomy Using the BRAVA Expansion System and Fat Grafting. *Plast Reconstr Surg Glob Open*. 2013 Dec 6;1(8):e71.
23. Seth I, Bulloch G, Gibson D, Chow O, Seth N, Mann GB, Hunter-Smith DJ, Rozen WM. Autologous Fat Grafting in Breast Augmentation: A Systematic Review Highlighting the Need for Clinical Caution. *Plast Reconstr Surg*. 2024 Mar 1;153(3):527e-538e. Epub 2023 May 2. PMID: 37166041.
24. State of Michigan. [The Insurance Code of 1956. MCLA 500. 3406a. Reconstructive surgery following mastectomy; prosthetic device.](#) ( Accessed April 2, 2025).
25. U.S. Department of Labor. [Women's Health and Cancer Rights Act of 1998.](#) ( Accessed April 2, 2025).
26. Vizcay M, et al. Current Fat Grafting Practices and Preferences: A Survey from Members of ISPRES. *Plast Reconstr Surg Glob Open*. 2023 Mar 29;11(3):e4849.

*Breast Specific Gamma Imaging (BSGI)*

27. Brem RF, Fishman M, Rapelyea JA. Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging, and magnetic resonance imaging: a comparative study. *Acad Radiol*. 2007;14(8):945-950.
28. Brem RF, Floerke AC, Rapelyea JA, et al. Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. *Radiology*. 2008;247(3):651-657.

29. Brem RF, Petrovitch I, Rapelyea JA, et al. Breast-specific gamma imaging with 99mTc-Sestamibi and magnetic resonance imaging in the diagnosis of breast cancer--a comparative study. *Breast J.* 2007;13(5):465-469.
30. Brem RF, Rapelyea JA, Zisman G, et al. Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer. *Radiology.* 2005;237(1):274-280. Epub 2005 Aug 26.
31. Brem RF, Schoonjans JM, Kieper DA, et al. High-resolution scintimammography: a pilot study. *J Nucl Med.* 2002;43(7):909-915.
32. Civelek AC, Patel P, Ozalp E, Brem RF. Tc-99m sestamibi uptake in the chest mimicking a malignant lesion of the breast. *Breast.* 2006;15(1):111-114.
33. Connolly LP, Drubach LA, Ted Treves S. Applications of nuclear medicine in pediatric oncology. *Clin Nucl Med.* 2002;27(2):117-125.
34. Leung JW. New modalities in breast imaging: digital mammography, positron emission tomography, and sestamibi scintimammography. *Radiol Clin North Am.* 2002 May;40(3):467-82. doi: 10.1016/s0033-8389(01)00004-5. PMID: 12117187.
35. Liberman M, Sampalis F, Mulder DS, Sampalis JS. Breast cancer diagnosis by scintimammography: A meta-analysis and review of the literature. *Breast Cancer Res Treat.* 2003;80(1):115-126.
36. National Academy of Sciences, Institute of Medicine, Committee on the Early Detection of Breast Cancer. *Mammography and Beyond: Developing Technologies for the Early Detection of Breast Cancer.* Washington, DC: National Academy Press; 2001.
37. O'Connor MK, Phillips SW, Hruska CB, et al. Molecular breast imaging: Advantages and limitations of a scintimammographic technique in patients with small breast tumors. *Breast J.* 2007;13(1):3-11.
38. Zhang Z, Wang W, Wang X, et al. Breast-specific gamma imaging or ultrasonography as adjunct imaging diagnostics in women with mammographically dense breasts. *Eur Radiol.* Jun 10 2020. PMID 32524221
39. Zhou M, Johnson N, Blanchard D, et al. Real-world application of breast-specific gamma imaging, initial experience at a community breast center and its potential impact on clinical care. *Am J Surg.* 2008;195(5):631-635.

#### *Male Gynecomastia*

40. Colombo-Benkmann M; Buse, B; Stern J; Herfarth C. Indications for and Results of Surgical Therapy for Male Gynecomastia, *American Journal of Surgery.* 1999 Jul;178(1):60-3.
41. Neuman, JF. Evaluation and Treatment of Gynecomastia, *American Family Physician.* 1997 Apr;55(5):1835-1844.
42. McGrath, M.H., Mukerji, S. Plastic surgery and the teenage patient. *J Pediatr Adolesc Gynecol.* 13:105-118, 2000.
43. Sher, E.S., Migeon, C.J., Berkovitz, G.D. Evaluation of boys with marked breast development at puberty. *Clin Pediatr.* 37:367-71, 1998.

44. Simon BE, Hoffman S, Kahn S. Classification and surgical correction of gynecomastia. *Plast Reconstr Surg.* 1973 Jan;51(1):48-52. doi: 10.1097/00006534-197301000-00009. PMID: 4687568.
45. American Society of Plastic Surgeons (ASPS). [Recommended Insurance Coverage Criteria for Third-Party Payers](#) ( Accessed April 2, 2025).
46. Volpe CM; Raffetto JD; Collure DW; Hoover EL; Doerr RJ. Unilateral Male Breast Masses: Cancer Risk and Their Evaluation, *The American Surgeon.* 1999 Mar;65(3):250-3.

#### *Mastectomy for Intractable Breast Pain*

47. Golshan, M. Breast Pain. In: UpToDate, Connor RF (Ed), Wolters Kluwer. Updated March 29,2024 (Accessed on April 3, 2024.)
48. Goyal, A et al. Breast Pain: Clinical Evidence Handbook. *American Family Physician*, May 2016; 93(10):872-873.

#### *Microsurgical Lymph Node Transplantation for Post mastectomy Lymphedema*

49. Becker et.al. Post mastectomy Lymphedema - long term results following Microsurgical Lymph Node Transplantation. *Annals of Surgery* Vol. 243, Number 3 March 2006 313-315.
50. Chang DW, et al. Surgical Treatment of Lymphedema: A Systematic Review and Meta-Analysis of Controlled Trials. Results of a Consensus Conference. *Plast Reconstr Surg.* 2021 Apr 1;147(4):975-993. PMID: 33761519.
51. Doubblestein D et al. Pre- and Post-Microsurgical Rehabilitation Interventions and Outcomes on Breast Cancer-Related Lymphedema: a Systematic Review. *Curr Oncol Rep.* 2023 Sep;25(9):1031-1046. Epub 2023 Jul 4. PMID: 37402044; PMCID: PMC10474983.

#### *Nerve Repair Procedures*

52. Bubberman JM, Van Rooij JAF, Van der Hulst RRWJ, Tuinder SMH. Sensory recovery and the role of innervated flaps in autologous breast reconstruction-a narrative review. *Gland Surg.* 2023 Aug 30;12(8):1094-1109. doi: 10.21037/gs-23-40. Epub 2023 Aug 11. PMID: 37701293; PMCID: PMC10493633.
53. Beugels J, Cornelissen AJM, van Kuijk SMJ, Lataster A, Heuts EM, Piatkowski A, Spiegel AJ, van der Hulst RRWJ, Tuinder SMH. Sensory Recovery of the Breast following Innervated and Noninnervated DIEP Flap Breast Reconstruction. *Plast Reconstr Surg.* 2019 Aug;144(2):178e-188e. PMID: 31348332.
54. Burns JR, Polyak TS, Pereira CT. Neurotization of the Nipple-Areola Complex during Implant-Based Reconstruction: Evaluation of Early Sensation Recovery. *Plast Reconstr Surg.* 2021 Jul 1;148(1):143e-144e. doi: 10.1097/PRS.00000000000008069. PMID: 34181625.
55. Chang TN, Lu JC, Sung CW, Illias AM, Cheong DC, Kao SW, Kuo WL, Pindur L, Chen LW, Lin JA, Chuang DC, Huang JJ. Elongation of intercostal nerve cutaneous branches for breast and nipple neurotization

- during breast reconstruction after mastectomy for breast cancer: case-control study. *Br J Surg*. 2024 Jan 31;111(2):znae005. doi: 10.1093/bjs/znae005. PMID: 38298070.
56. Djohan R, Scomacao I, Knackstedt R, Cakmakoglu C, Grobmyer SR. Neurotization of the Nipple-Areola Complex during Implant-Based Reconstruction: Evaluation of Early Sensation Recovery. *Plast Reconstr Surg*. 2020 Aug;146(2):250-254. doi: 10.1097/PRS.0000000000006976. PMID: 32740571.
57. Morris BE, Van Spronsen NR, Shrout MA, Teven CM, Rebecca AM. Neurotization during Breast Reconstruction. *Plast Reconstr Surg Glob Open*. 2022 Nov 16;10(11):e4591. PMID: 36405045; PMCID: PMC9668545.
58. Vartanian ED, Lo AY, Hershenhouse KS, Jacob L, Patel KM. The role of neurotization in autologous breast reconstruction: Can reconstruction restore breast sensation? *J Surg Oncol*. 2021 Apr;123(5):1215-1231. doi: 10.1002/jso.26422. Epub 2021 Feb 23. PMID: 33621375.
59. Weissler JM, Koltz PF, Carney MJ, Serletti JM, Wu LC. Sifting through the Evidence: A Comprehensive Review and Analysis of Neurotization in Breast Reconstruction. *Plast Reconstr Surg*. 2018 Mar;141(3):550-565. doi: 10.1097/PRS.0000000000004108. PMID: 29481387.

#### *Reduction Mammoplasty*

60. Perdakis Get al. American Society of Plastic Surgeons Evidence-Based Clinical Practice Guideline Revision: Reduction Mammoplasty. *Plast Reconstr Surg*. 2022 Mar 1;149(3):392e-409e. PMID: 35006204.
61. Mistiaen P, et al. Prevention and treatment of intertrigo in large skin folds of adults: a systematic review. *BMC Nurs*. 2010 Jul 13;9:12. PMID: 20626853;
- 62.
63. Teller Pet al. Innovation in Breast Surgery: Practical and Ethical Considerations. *Ann Surg Oncol*. 2022 Oct;29(10):6144-6150. Epub 2022 Jul 19. PMID: 35854028.
64. Wisconsin Physicians Service (WPS), [Local Coverage Decision \(L39051\) Cosmetic and Reconstructive Surgery](#) (Accessed April 2, 2025).

#### *Screening Mammography, Digital Breast Tomosynthesis (DBT), Ultrasound, Thermography, Electrical Impedance Scanning, and Breast MRI*

65. Akhtari-Zavare M, et al. Electrical Impedance Tomography as a Primary Screening Technique for Breast Cancer Detection. *Asian Pac J Cancer Prev*. 2015;16(14):5595-7. doi: 10.7314/apjcp.2015.16.14.5595. PMID: 26320422.
66. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. *CA Cancer J Clin* 2007;57:75–89
67. American Cancer Society. [Breast Density and Your Mammogram Report](#) (Last Revised September 9, 2024). (Accessed April 2, 2025).



68. American College of Radiology. Breast Density, Breast Cancer Screening. Available at [https://www.acr.org/-/media/ACR/Files/Breast-Imaging-Resources/Breast-Density-bro\\_ACR\\_SBI.pdf](https://www.acr.org/-/media/ACR/Files/Breast-Imaging-Resources/Breast-Density-bro_ACR_SBI.pdf) (Retrieved April 5, 2024).
69. American College of Radiology. Digital Breast Tomosynthesis (DBT) Guidance: A supplement to ACR BI-RADS Mammography 2013. Available at <https://www.acr.org/-/media/ACR/Files/RADS/BI-RADS/BI-RADS-Digital-Breast-Tomosynthesis-Supplement.pdf> (Retrieved April 5, 2024).
70. Berg WA, Bandos AI, Mendelson EB, Lehrer D, Jong RA, Pisano ED. Ultrasound as the Primary Screening Test for Breast Cancer: Analysis From ACRIN 6666. *J Natl Cancer Inst.* 2015 Dec 28;108(4):djv367. doi: 10.1093/jnci/djv367. PMID: 26712110; PMCID: PMC5943835.
71. Coroneos CJ, Wong FC, DeSnyder SM, Shaitelman SF, Schaverien MV. Correlation of L-Dex Bioimpedance Spectroscopy with Limb Volume and Lymphatic Function in Lymphedema. *Lymphat Res Biol.* 2019 Jun;17(3):301-307. Epub 2018 Nov 2. PMID: 30388062.
72. D'Orsi CJ, Sickles EA, Mendelson EB, Morris EA, et al. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Reston, VA, American College of Radiology; 2013.
73. Gunnarsson GL, Bille C, Reitsma LC, Wamberg P, Thomsen JB. Prophylactic Nipple-Sparing Mastectomy and Direct-to-Implant Reconstruction of the Large and Ptotic Breast: Is Preshaping of the Challenging Breast a Key to Success? *Plast Reconstr Surg.* 2017 Sep;140(3):449-454. PMID: 28841601.
74. Hidding JT, Viehoff PB, Beurskens CH, van Laarhoven HW, Nijhuis-van der Sanden MW, van der Wees PJ. Measurement Properties of Instruments for Measuring of Lymphedema: Systematic Review. *Phys Ther.* 2016 Dec;96(12):1965-1981. doi: 10.2522/ptj.20150412. Epub 2016 Jun 23. PMID: 27340195.
75. Hope TA, Iles SE. Technology review: the use of electrical impedance scanning in the detection of breast cancer. *Breast Cancer Res.* 2004;6(2):69-74. doi: 10.1186/bcr744. Epub 2003 Nov 13. PMID: 14979909; PMCID: PMC400648.
76. Houssami N, Skaane P. Overview of the evidence on digital breast tomosynthesis in breast cancer detection. *Breast.* 2013 Apr;22(2):101-108. doi: 10.1016/j.breast.2013.01.017. Epub 2013 Feb 16. PMID: 23422255.
77. Jung M, et al. Reference values of bioelectrical impedance analysis for detecting breast cancer-related lymphedema. *Medicine (Baltimore).* 2018 Nov;97(44):e12945.
78. Kilgore LJ, et al. Reducing Breast Cancer-Related Lymphedema (BCRL) Through Prospective Surveillance Monitoring Using Bioimpedance Spectroscopy (BIS) and Patient Directed Self-Interventions. *Ann Surg Oncol.* 2018 Oct;25(10):2948-2952.
79. Koelmeyer La, et al. Early surveillance is associated with less incidence and severity of breast cancer-related lymphedema compared with a traditional referral model of care. *Cancer.* 2019 Mar 15;125(6):854-862.

80. Kopans DB, Skaane P. Digital breast tomosynthesis: a better mammogram. *Radiology*. 2013 Jun;267(3):968-9. doi: 10.1148/radiol.13130086
81. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. *N Engl J Med*. 2004;351(5):427-437.
82. Liberman, L. Breast Cancer Screening with MRI—What are the Data for Patients at High Risk? *New England Journal of Medicine*, 351; 5, July 29, 2004, pp. 497-500
83. Lim GH, Baidam AD. Novel Approach for Risk-Reducing Mastectomy: First-Stage Implant Placement and Subsequent Second-Stage Mastectomy. *Plast Reconstr Surg*. 2018 Sep;142(3):607-610. doi: 10.1097/PRS.0000000000004635. PMID: 29878997.
84. Monticciolo DL, et al. Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. *J Am Coll Radiol*. 2023 Sep;20(9):902-914. doi: 10.1016/j.jacr.2023.04.002. Epub 2023 May 5. PMID: 37150275.
85. McLaughlin SA, et al. Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema: Recommendations from a Multidisciplinary Expert ASBrS Panel Part 1: Definitions, Assessments, Education, and Future Directions. *Ann Surg Oncol* (2017) 24:2818–2826.
86. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Screening and Diagnosis. Version 2.2025.
87. Rakhunde et al. Thermography as a Breast Cancer Screening Technique: A Review Article. *Cureus*. 2022 Nov 8;14(11):e31251. doi: 10.7759/cureus.31251. PMID: 36505165; PMCID: PMC9731505.
88. Rezanejad Gatabi Z, et al. The Accuracy of Electrical Impedance Tomography for Breast Cancer Detection: A Systematic Review and Meta-Analysis. *Breast J*. 2022 May 26;2022:8565490. doi: 10.1155/2022/8565490. PMID: 35711881; PMCID: PMC9186524.
89. Seward C, et al. A comprehensive review of bioimpedance spectroscopy as a diagnostic tool for the detection and measurement of breast cancer-related lymphedema. *J Surg Oncol*. 2016 Oct;114(5):537-542.
90. Shah C, et al. The impact of early detection and intervention of breast cancer-related lymphedema: a systematic review. *Cancer Med*. 2016 Jun;5(6):1154-62.
91. Skaane P, Bandos AI, Gullien R, Eben EB, et al. Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitration. *Eur Radiol*. 2013 Aug;23(8):2061-71. doi: 10.1007/s00330-013-2820-3. Epub 2013 Apr 4. PMID: 23553585; PMCID: PMC3701792.
92. State of Michigan. [The Insurance Code of 1956. 500.3406d Coverage for breast cancer diagnostic services, breast cancer outpatient treatment](#)



[services, and breast cancer rehabilitative services; coverage for breast cancer screening mammography; definitions](#). MCLA 500. 3406d. (Accessed April 2, 2025).

93. Steele ML, et al. Normative Interlimb Impedance Ratios: Implications for Early Diagnosis of Uni- and Bilateral, Upper and Lower Limb Lymphedema. *Lymphat Res Biol*. 2018 Oct 2.
94. Vicini F, et al. Correlation of Bioimpedance Spectroscopy with Risk Factors for the Development of Breast Cancer-Related Lymphedema. *Lymphat Res Biol*. 2018 Dec 1; 16(6): 533–537.
95. Waldherr C, Cerny P, Altermatt HJ, Berclaz G, Ciriolo M, Buser K, Sonnenschein MJ. Value of one-view breast tomosynthesis versus two-view mammography in diagnostic workup of women with clinical signs and symptoms and in women recalled from screening. *AJR Am J Roentgenol*. 2013 Jan;200(1):226-31. doi: 10.2214/AJR.11.8202.
96. Wang T et al. Prospective study on combination of electrical impedance scanning and ultrasound in estimating risk of development of breast cancer in young women. *Cancer Invest*. Mar 2010;28(3):295-303.
97. Whitworth PW and Cooper A. Reducing chronic breast cancer-related lymphedema utilizing a program of prospective surveillance with bioimpedance spectroscopy. *Breast J*. 2018 Jan;24(1):62-65.
98. Whitworth PW, et al. Preventing Breast Cancer-Related Lymphedema in High-Risk Patients: The Impact of a Structured Surveillance Protocol Using Bioimpedance Spectroscopy. *Front Oncol*. 2018 Jun 12;8:197.
99. Xie AST, et al. Diagnosing Male Unilateral Upper Limb Lymphedema: Determination of Normatively Determined Thresholds Using Bioimpedance Spectroscopy. *Lymphat Res Biol*. 2019 Mar 5.

**AMA CPT Copyright Statement:**

All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

---

*This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion.*

*Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.*

*The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.*